Biolegend, 505817, Pacific Blue™ anti-mouse IFN-γ Antibody, 25μg

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli-expressed, recombinant mouse IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses
Excitation Laser: Violet Laser (405 nm)
Application Notes: ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations. Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut) Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut) Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut) Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT) Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC) Ferrick D, et al. 1995. Nature 373:255. (FC) Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut) DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Montfort M, et al.2004. J. Immunol. 173:4084. PubMed Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC) Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations: Li P, et al. 2020. J Cell Mol Med. 24:10151. PubMed Cha JH et al. 2018. Molecular cell. 71(4):606-620 . PubMed Djoki&cacute; V, et al. 2019. Front Immunol. 9:2891. PubMed Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed Tian J, et al. 2022. J Immunol Res. 2022:4012920. PubMed Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed Yin Y, et al. 2021. ACS Nano. 15:14347. PubMed Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed Ma YS, et al. 2021. Mol Ther Oncolytics. 484:20. PubMed Coomes S, et al. 2015. PLoS One. 11: 1004994. PubMed He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed Coursey T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.83. PubMed Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed Jia Q, et al. 2021. Theranostics. 4699:11. PubMed Milner JJ, et al. 2020. Immunity. 52(5):808-824.e7. PubMed He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed Qian M, et al. 2020. Aging (Albany NY). 12:17122. PubMed Xiao Y, et al. 2018. Int Immunol. 30:457. PubMed Montfort M, et al. 2004. J Immunol. 173:4084. PubMed Li Z, et al. 2020. Front Cell Dev Biol. 8:572689. PubMed Lee J, et al. 2007. Nat Immunol. 8:181. PubMed He X, et al. 2021. J Immunother Cancer. 9:. PubMed Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed Mak'Anyengo R, et al. 2018. JCI Insight. 3:e96322. PubMed Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
RRID: AB_528922 (BioLegend Cat. No. 505817) AB_893526 (BioLegend Cat. No. 505818)
Structure: Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources: CD8+ and CD4+ T cells, NK cells
Cell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID: 15978
UniProt: View information about IFN-gamma on UniProt.org
Clone: XMG1.2
Regulatory Status: RUO
Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype: Rat IgG1, κ